Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 1, 2020
CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office...
-
Sep 28, 2020HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of age and older
KING OF PRUSSIA, PA – September 28, 2020 – CSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication...
Sep 24, 2020The study narrowly missed statistical significance on the primary endpoint Pre-specified adjustment of COVID-19 impact, the study showed a statistically significant advantage The totality of...
-
Sep 18, 2020
Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF 435 In addition Vifor Pharma obtains an earn out related to potential future value gains on 20% of...
-
Sep 7, 2020
CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19...
-
Sep 4, 2020- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness
MARBURG, Germany 4 September 2020 - CSL Behring a global biotherapeutics leader announced today that the company will host a symposium focused on the challenges of treating lung disease in the...
-
Sep 1, 2020Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee
St Gallen, September 1, 2020 – Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1,...
-
Aug 18, 2020
Development of the University of Queensland’s vaccine candidate remains CSL’s priority. However, we are currently in discussions with AstraZeneca and the Australian Government to assess...
-
Aug 6, 2020
Net sales and EBITDA continued to grow in H1 2020 despite challenging market conditions due to COVID-19 Ferinject®/ Injectafer® demand impacted by global COVID-19 restrictions Sustained growth...
-
Jul 30, 2020
Washington, D.C., July 30, 2020 – At today’s White House Roundtable, plasma industry leader and CSL CEO Paul Perreault urged people who have recovered from COVID-19 to consider donating plasma...